All lobbying filings

BRIDGEBIO PHARMA, INC.

BRIDGEBIO PHARMA, INC. filed a Q1 report for BRIDGEBIO PHARMA, INC. on April 20, 2026.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

All filings by BRIDGEBIO PHARMA, INC. · Everything BRIDGEBIO PHARMA, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$420,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Lobbyists on this filing 1

TRIPP ADAMS New on this filing

Previously held: Staff Assistant and Legislative Correspondent for Sen. Johnny Isakson; Legislative Correspondent for Sen. Kelly Loeffler; Health Research Assistant and Staff Member for the Senate Health, Education, Labor and Pensions Committee.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

H.R.7148 - Consolidated Appropriations Act, 2026 Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Orphan drug policies General issues and provisions related to PBM Reform

Bills named in this filing 2

H.R. 7148
Consolidated Appropriations Act, 2026
H.R. 1262
Mikaela Naylon Give Kids a Chance Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.